| 1 |
Cree IA. The WHO classification of haematolymphoid tumours[J]. Leukemia, 2022, 36 (7): 1701-1702.
|
| 2 |
Guru Murthy GS, Dhakal I, Mehta P. Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States[J]. Leuk Lymphoma, 2017, 58 (7): 1648-1654.
|
| 3 |
Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management[J]. Am J Hematol, 2020, 95 (1): 97-115.
|
| 4 |
Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts[J]. BMC Med, 2014 (12): 119.
|
| 5 |
Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes[J]. Leukemia, 2013, 27 (7): 1504-1510.
|
| 6 |
Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia[J]. Leukemia, 2013, 27 (7): 1441-1450.
|
| 7 |
Patnaik MM, Parikh SA, Hanson CA, et al. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review[J]. Br J Haematol, 2014, 165 (3): 273-286.
|
| 8 |
Fagniez O, Tertian G, Dreyfus M, et al. Hematological disorders related cerebral infarctions are mostly multifocal[J]. J Neurol Sci, 2011, 304 (1-2): 87-92.
|
| 9 |
王玉洁，曲同庆，秦俊义.以脑梗死为首发症状的急性粒-单核细胞白血病（M4b型）1例报道[J].卒中与神经疾病，2004,11(1):7-7.
|
| 10 |
耿立霞，王永福，李光海，等.以急性心肌梗死和脑梗死为首发症状的急性髓性白血病一例并文献复习[J/CD].中华危重症医学杂志（电子版），2009,2(1):45-47.
|
| 11 |
Dunbar AJ, Gondek LP, O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies[J]. Cancer Res, 2008, 68 (24): 10349-10357.
|
| 12 |
Wang J, Kong G, Liu Y, et al. NrasG12D/+ promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions[J]. Blood, 2013, 121 (26): 5203-5207.
|
| 13 |
You X, Liu F, Binder M, et al. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation[J]. Blood, 2022, 139 (7): 1066-1079.
|
| 14 |
Kong G, Wunderlich M, Yang D, et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm[J]. J Clin Invest, 2014, 124 (6): 2762-2773.
|